drugset
drugset / Trial / NCT00100789

S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

NCT00100789 ↗

Phase 2 Completed 67 enrolled SWOG Cancer Research Network National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine together with paclitaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with paclitaxel works in treating patients with persistent, recurrent, or metastatic head and neck cancer.

Timeline

Start
2005-01
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 3000 mg/m2 Intravenous
Subject Paclitaxel Small molecule 150 mg/m2 Intravenous

Indications

head and neck cancer